<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045292</url>
  </required_header>
  <id_info>
    <org_study_id>1603.00</org_study_id>
    <secondary_id>FHCRC-1603.00</secondary_id>
    <secondary_id>NCI-H02-0092</secondary_id>
    <secondary_id>CDR0000256871</secondary_id>
    <nct_id>NCT00045292</nct_id>
  </id_info>
  <brief_title>Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation</brief_title>
  <official_title>A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in
      preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing
      cytomegalovirus in patients undergoing stem cell transplantation.

      PURPOSE: Randomized phase III trial to determine the effectiveness of valacyclovir in
      preventing cytomegalovirus in patients who are undergoing donor stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the occurrence of serious invasive fungal or bacterial infections during the
           first 270 days after transplantation in cytomegalovirus (CMV)-negative patients
           receiving a CMV-positive allogeneic stem cell transplantation and valacyclovir or
           placebo.

        -  Compare the occurrence of primary CMV infection within the first 100 days after
           transplantation in patients treated with these regimens.

        -  Compare the survival of these patients at 100 days and 270 days post-transplantation.

        -  Compare the occurrence of CMV disease at day 100 and day 270 post-transplantation in
           patients treated with these regimens.

        -  Compare the safety of these regimens in these patients.

        -  Correlate the presence of CMV in stem cell product with post-transplantation CMV
           infection in these patients.

        -  Determine if subclinical CMV infection results in a virus-specific immune response
           (humoral and cellular) in these patients.

        -  Compare the quality of life of patients treated with these regimens.

        -  Compare resource utilization (e.g., rates of hospitalization, number of days alive out
           of the hospital, days in the intensive care unit, days on mechanical ventilation, use of
           antimicrobials and filgrastim [G-CSF], and number of invasive procedures) in patients
           treated with these regimens.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
      are stratified according to participating center and type of transplantation (matched related
      vs mismatched/unrelated). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive oral valacyclovir 4 times daily beginning with transplantation
           conditioning (usually day -5) and continuing until day 100 after transplantation.
           Patients receive high-dose acyclovir, instead of valacyclovir, IV every 8 hours
           beginning on day -1 and continuing until oral medications are tolerated. Allogeneic stem
           cells are infused on day 0.

        -  Arm II: Patients receive oral or IV placebo on the same schedule as in arm I. Quality of
           life is assessed at baseline and on days 50 and 100.

      Patients are followed every 2 weeks for 6 months.

      PROJECTED ACCRUAL: A total of 115-230 patients (58-115 per treatment arm) will be accrued for
      this study within 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acyclovir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acyclovir sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valacyclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Disease requiring one of the following types of stem cell transplantation:

               -  First myeloablative allogeneic peripheral blood stem cell

               -  Unrelated cord blood

               -  Bone marrow

                    -  Related or unrelated donor

                    -  T-cell depleted or non-T-cell depleted

                    -  CD34 selected or non-selected

          -  Patient must be cytomegalovirus (CMV)-seronegative and donor must be CMV-seropositive

          -  No transplantation with nonmyeloablative regimens, including any of the following:

               -  Fludarabine and total body irradiation (TBI) (2 Gy or less)

               -  TBI alone (2 Gy)

               -  Fludarabine, cytarabine, and idarubicin

               -  Fludarabine and melphalan (140 mg/m^2 or less)

          -  No definite or probable pre-transplantation diagnosis of invasive mold infection
             (aspergillosis, fusariosis, or zygomycosis), including pulmonary or hepatic nodules
             consistent with invasive mold infection for which patients are receiving targeted
             prophylaxis with amphotericin or other mold-active products

          -  No pre-transplantation-CMV disease (gastrointestinal or pneumonia)

        PATIENT CHARACTERISTICS:

        Age

          -  12 and over

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  HIV negative

          -  No hypersensitivity to acyclovir or valacyclovir

          -  Not pregnant

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  See Disease Characteristics

        Chemotherapy

          -  See Disease Characteristics

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  See Disease Characteristics

        Surgery

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Garrett Nichols, MD, MSC</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center at Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-3330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 17, 2010</last_update_submitted>
  <last_update_submitted_qc>September 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2010</last_update_posted>
  <keyword>infection</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>untreated childhood acute myeloid leukemia and other myeloid malignancies</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>poor prognosis metastatic gestational trophoblastic tumor</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent Wilms tumor and other childhood kidney tumors</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

